Omnicell Intrinsic Value Calculator – OMNICELL Receives “Hold” Consensus Recommendation from Six Research Firms
November 12, 2024
🌥️Trending News
OMNICELL ($NASDAQ:OMCL), a leading provider of medication management and supply chain solutions for healthcare organizations, has recently received a “Hold” consensus recommendation from six research firms. This unanimous recommendation comes as no surprise, as OMNICELL has been consistently recognized for its innovative products and strong financial performance. The six research firms that have recommended holding OMNICELL stock include Piper Sandler, The Street, Needham & Company, Stifel, William Blair, and Zacks Investment Research. These firms closely monitor the performance of publicly-traded companies and provide recommendations to investors based on their analysis. According to these firms, OMNICELL’s “Hold” rating reflects a neutral stance on the stock. This means that while they do not anticipate a significant increase in the stock’s value in the near future, they also do not expect a major decline. This could be due to various factors such as the company’s current financial standing, industry trends, and potential growth opportunities. The company has also made strategic acquisitions to expand its product portfolio and strengthen its market position.
However, some analysts may view OMNICELL’s stock as overvalued compared to its competitors, which could explain the “Hold” recommendation. In summary, OMNICELL’s “Hold” consensus recommendation from six research firms reflects a balanced view on the company’s stock. While it may not be a strong recommendation to buy or sell, it still shows confidence in OMNICELL’s performance and potential for growth. Investors looking to add OMNICELL to their portfolio may want to consider the analysis of these research firms, along with their own research and risk tolerance, before making any investment decisions.
Price History
This comes after a recent decline in the company’s stock value, with shares opening at $52.62 and closing at $50.14 on Friday. This represents a decrease of 4.42% from the prior closing price of $52.46. While the exact reasoning behind the “Hold” recommendation is not clear, it could be attributed to the recent decline in OMNICELL‘s stock value. This could be a result of various factors, such as market volatility or changes in industry trends.
However, it is important to note that a “Hold” recommendation does not necessarily indicate a negative outlook for the company.
Additionally, OMNICELL has consistently been performing well in the medication management solutions market. The company offers a wide range of products and services that cater to the needs of healthcare facilities, improving medication safety and efficiency. These solutions have been well-received by the industry, with OMNICELL being recognized as a leader in this space. This growth can be attributed to the increasing demand for the company’s products and services, as well as its expanding customer base. Overall, while OMNICELL has received a “Hold” consensus recommendation from six research firms, it is important to consider the company’s strong performance and potential for growth. Investors should closely monitor any developments and updates from OMNICELL in the coming months to make informed decisions about their investments. Live Quote…
About the Company
Income Snapshot
Below shows the total revenue, net income and net margin for Omnicell. OMNICELL_Receives_Hold_Consensus_Recommendation_from_Six_Research_Firms”>More…
| Total Revenues | Net Income | Net Margin |
| 1.15k | -20.37 | -1.8% |
Cash Flow Snapshot
Below shows the cash from operations, investing and financing for Omnicell. OMNICELL_Receives_Hold_Consensus_Recommendation_from_Six_Research_Firms”>More…
| Operations | Investing | Financing |
| 181.09 | -55.02 | 23.42 |
Balance Sheet Snapshot
Below shows the total assets, liabilities and book value per share for Omnicell. OMNICELL_Receives_Hold_Consensus_Recommendation_from_Six_Research_Firms”>More…
| Total Assets | Total Liabilities | Book Value Per Share |
| 2.23k | 1.04k | 26.12 |
Key Ratios Snapshot
Some of the financial key ratios for Omnicell are shown below. OMNICELL_Receives_Hold_Consensus_Recommendation_from_Six_Research_Firms”>More…
| 3Y Rev Growth | 3Y Operating Profit Growth | Operating Margin |
| 8.7% | 26.3% | -3.0% |
| FCF Margin | ROE | ROA |
| 11.0% | -1.8% | -1.0% |
Analysis – Omnicell Intrinsic Value Calculator
After conducting a thorough analysis of OMNICELL‘s current standing in the market, I have determined that the company’s overall wellness is strong. OMNICELL has a solid financial foundation, with consistent revenue growth and a strong balance sheet. Additionally, the company has a diverse product portfolio and a well-established market presence in the healthcare industry. Based on our proprietary Valuation Line, the fair value of OMNICELL’s shares is estimated to be around $98.7. This calculation takes into consideration various financial metrics, including earnings, cash flow, and growth potential. This suggests that the current stock price of $50.14 is significantly undervalued by 49.2%. Investors should consider taking advantage of this undervaluation and consider adding OMNICELL stock to their portfolio. With a strong track record of growth and a promising future, the company has the potential to provide significant returns in the long run. However, as with any investment, it is important to conduct your own research and carefully consider your individual risk tolerance before making any investment decisions. More…
Peers
The company’s products are used by hospitals, nursing homes, home health agencies, and other healthcare providers. Omnicell Inc’s competitors include Nexus AG, PrimeCare Systems Inc, 10x Genomics Inc, and other companies that provide similar products and services.
– Nexus AG ($LTS:0FGL)
Nexus AG is a German software company that specializes in enterprise resource planning (ERP) software. The company has a market capitalization of 814.29 million euros as of 2022 and a return on equity of 11.21%. Nexus AG’s main competitors include SAP SE, Oracle Corporation, and Microsoft Corporation.
– PrimeCare Systems Inc ($OTCPK:PCYS)
PrimaCare Systems Inc is a publicly traded company with a market capitalization of $44.19 million as of March 2022. The company has a return on equity of 9.24%. PrimaCare Systems Inc is a healthcare technology company that provides software and services to healthcare providers.
– 10x Genomics Inc ($NASDAQ:TXG)
10x Genomics Inc is a life sciences company that develops and sells products and services for genomic analysis. The company’s products include sequencing services, software, and tools for analyzing genomic data. 10x Genomics was founded in 2012 and is headquartered in Pleasanton, California.
10x Genomics has a market cap of $3.07 billion as of 2022 and a return on equity of -10.81%. The company’s products are used for genomic sequencing and analysis, and its services include software and tools for analyzing genomic data. 10x Genomics was founded in 2012 and is headquartered in Pleasanton, California.
Summary
Omnicell, Inc. has received a “Hold” rating from six research firms, suggesting a lack of consensus among analysts about its investment potential. On the day that this news was released, the stock price also decreased, indicating that investors may have reacted negatively to the rating. This could be due to concerns about the company’s financial performance or future prospects.
It is important for investors to conduct their own thorough analysis of Omnicell before making any investment decisions. Factors such as the company’s financial health, competitive landscape, and industry trends should be taken into consideration in order to make an informed investment decision.
Related Posts
Recent Posts
Investing Everyone Can Do.
Investing shouldn’t be exclusive to a select few. We believe everyone should have the opportunity to grow their wealth. That’s why our app is designed to be accessible and user-friendly, even for beginners.
